Vimizim (Elosulfase alfa Vials) 1mg/ml x5ml

Vimizim (elosulfase alfa) is an enzyme replacement therapy for mucopolysaccharidosis type IVA (Morquio A syndrome). This 1mg/ml x5ml vial formulation supports metabolic health in rare genetic conditions. Store between 2-8°C to maintain potency. Not intended for self-administration without medical supervision.

Strength

1mg/ml x5ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

BioMarin International Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Vimizim is used to treat mucopolysaccharidosis type IVA, a rare metabolic disorder affecting bone and joint development. It replaces deficient enzymes to improve mobility and respiratory function. Patients and caregivers often ask what is elosulfase alfa used for and how it supports metabolic health in Morquio A syndrome.

Side Effects

Vimizim helps manage symptoms by addressing the underlying enzyme deficiency in Morquio A syndrome. Common effects include improved endurance and reduced joint stiffness over time. Individual responses may vary based on disease progression and treatment consistency.

Precautions & Warnings

Vimizim requires careful handling due to its refrigerated storage needs (2-8°C). Always check vial clarity before use; discard if particles or discoloration appear. Administration should be supervised by a healthcare professional to monitor for infusion-related reactions.

Avoid Interactions

Limited data exists on drug interactions with elosulfase alfa. Caution is advised when combining with other therapies targeting metabolic pathways. Patients should disclose all medications to their healthcare provider before starting Vimizim to assess potential risks.

Frequently Asked Questions

Elosulfase alfa is used to treat mucopolysaccharidosis type IVA (Morquio A syndrome), a rare genetic disorder affecting bone and joint development.

Vimizim is administered via intravenous infusion under medical supervision, typically in a clinical setting.

No, Vimizim must be stored between 2-8°C to maintain its effectiveness and should not be exposed to room temperature for extended periods.

Common effects may include infusion-related reactions such as fever, headache, or nausea. Always consult a healthcare provider for personalized advice.

No, Vimizim is a prescription medication and requires medical supervision for administration.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.